The brain microvasculature is a primary mediator of interferon-α neurotoxicity in human cerebral interferonopathies.

Aicardi-Goutières syndrome blood-brain barrier cerebral interferonopathy endothelial interferon-alpha microangiopathy neuroinflammation neurotoxicity small vessel disease

Journal

Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918

Informations de publication

Date de publication:
11 Jun 2024
Historique:
received: 22 02 2022
revised: 10 01 2024
accepted: 17 05 2024
medline: 16 6 2024
pubmed: 16 6 2024
entrez: 15 6 2024
Statut: aheadofprint

Résumé

Aicardi-Goutières syndrome (AGS) is an autoinflammatory disease characterized by aberrant interferon (IFN)-α production. The major cause of morbidity in AGS is brain disease, yet the primary source and target of neurotoxic IFN-α remain unclear. Here, we demonstrated that the brain was the primary source of neurotoxic IFN-α in AGS and confirmed the neurotoxicity of intracerebral IFN-α using astrocyte-driven Ifna1 misexpression in mice. Using single-cell RNA sequencing, we demonstrated that intracerebral IFN-α-activated receptor (IFNAR) signaling within cerebral endothelial cells caused a distinctive cerebral small vessel disease similar to that observed in individuals with AGS. Magnetic resonance imaging (MRI) and single-molecule ELISA revealed that central and not peripheral IFN-α was the primary determinant of microvascular disease in humans. Ablation of endothelial Ifnar1 in mice rescued microvascular disease, stopped the development of diffuse brain disease, and prolonged lifespan. These results identify the cerebral microvasculature as a primary mediator of IFN-α neurotoxicity in AGS, representing an accessible target for therapeutic intervention.

Identifiants

pubmed: 38878770
pii: S1074-7613(24)00271-1
doi: 10.1016/j.immuni.2024.05.017
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests I.L.C. and M.J.H. received funding from Ionis Pharmaceuticals for experiments in an unrelated study using the GIFN mice.

Auteurs

Barney Viengkhou (B)

School of Life and Environmental Sciences and the Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.

Emina Hayashida (E)

School of Life and Environmental Sciences and the Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.

Sarah McGlasson (S)

UK Dementia Research Institute at University of Edinburgh, Edinburgh EH16 4SB, UK; Centre for Clinical Brain Sciences at University of Edinburgh, Edinburgh EH16 4SB, UK.

Katie Emelianova (K)

UK Dementia Research Institute at University of Edinburgh, Edinburgh EH16 4SB, UK.

Deborah Forbes (D)

UK Dementia Research Institute at University of Edinburgh, Edinburgh EH16 4SB, UK; Centre for Clinical Brain Sciences at University of Edinburgh, Edinburgh EH16 4SB, UK.

Stewart Wiseman (S)

Centre for Clinical Brain Sciences at University of Edinburgh, Edinburgh EH16 4SB, UK.

Joanna Wardlaw (J)

UK Dementia Research Institute at University of Edinburgh, Edinburgh EH16 4SB, UK; Centre for Clinical Brain Sciences at University of Edinburgh, Edinburgh EH16 4SB, UK.

Rovin Verdillo (R)

School of Life and Environmental Sciences and the Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.

Sarosh R Irani (SR)

Oxford Autoimmune Neurology Group, University of Oxford, Oxford, UK.

Darragh Duffy (D)

Translational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.

Fredrik Piehl (F)

Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Lipin Loo (L)

School of Life and Environmental Sciences and the Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.

Axel Pagenstecher (A)

Department of Neuropathology, University of Marburg, Baldingerstrasse, 35043 Marburg, Germany.

G Greg Neely (GG)

School of Life and Environmental Sciences and the Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.

Yanick J Crow (YJ)

MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK; Laboratory of Neurogenetics and Neuroinflammation, Institut Imagine, Université de Paris, Paris, France.

Iain L Campbell (IL)

School of Life and Environmental Sciences and the Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.

David P J Hunt (DPJ)

UK Dementia Research Institute at University of Edinburgh, Edinburgh EH16 4SB, UK; Centre for Clinical Brain Sciences at University of Edinburgh, Edinburgh EH16 4SB, UK. Electronic address: david.hunt@ed.ac.uk.

Markus J Hofer (MJ)

School of Life and Environmental Sciences and the Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: markus.hofer@sydney.edu.au.

Classifications MeSH